Abbott has announced that they are partnering with Medtronic Diabetes to connect a continuous glucose monitor (CGM) based on Abbott’s FreeStyle Libre tech with their insulin delivery systems
The integration of Abbott’s CGM sensor with Medtronic’s AID algorithms will enable automatic adjustments of insulin to keep glucose in range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.
AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin.
“This partnership pairs two global leaders in glucose sensing technology and insulin delivery,” said Jared Watkin, executive vice president of Abbott’s diabetes care business. “Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”
To find out more, CLICK HERE.
